Stockreport

Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]

Nuvalent, Inc. - Class A  (NUVL) 
NASDAQ:AMEX Investor Relations: nuvelinc.com/company/investor_relations.html
PDF Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review; P [Read more]